Chelsea Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
CHARLOTTE, N.C., Feb. 3, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 12th Annual BIO CEO & Investor Conference at 1:30 PM ET on Tuesday, February 9th at the Waldorf Astoria Hotel in New York City.
In addition to a brief overview of the company's product pipeline, clinical development status and key upcoming milestones, Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will announce the final trial design for Chelsea’s new Phase III trial of Droxidopa in neurogenic orthostatic hypotension as well as provide additional details on the design of the company’s Phase II trial of CH-4051 in rheumatoid arthritis. Both studies are expected to begin next quarter.
Dr. Pedder’s presentation will be webcast live and archived for 90 days on Chelsea’s website, www.chelseatherapeutics.com.
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).
This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates Droxidopa and CH-1504, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing and reliance on key personnel including specifically Dr. Pedder.
CONTACT: Chelsea Therapeutics
Investors:
Kathryn McNeil
718-788-2856
mcneil@chelseatherapeutics.com